Events

Vincent CORVEST, Senior Scientist & Business Manager at CALIXAR, will be pleased to present the poster “Toolbox For native Membrane Targets” during the Discovery On Target (DOT) event in Boston, from October 17 to 20, 2022. You will discover the CALIXAR fully native process to customize membrane proteins, look at our developing pipeline, and discuss your challenging targets to identify potential collaboration. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth €70 bn by 2025 Meet Vincent during these 4 days of event to learn more on CALIXAR’s proprietary technology and exchange with him about your targets to secure the generation of new drugs, antibodies, or small molecules. About Discovery Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. For more information: Discovery On Target 2022  

CALIXAR will join the International Research Network (IRN) on GPCRs as a sponsor for the 2nd IRN I-GPCRNET Annual Meeting at the University of Wurzburg (Germany), from September 30th to October 1st, 2022. Amélia CHORFA, post-doctoral at CALIXAR, will present during this event herPhD work carried out at the Institute of Functional Genomics in Montpellier in the team of Bernard Mouillac and Sébastien Granier. She worked on the characterization of effects of Mambaquaretin (toxin from green mamba venom) on renal cancer by targeting Vasopressin type 2 receptor (V2R), a GPCR responsible to antidiuresis. By in vitro and in vivo models, she shown that Mambaquaretin is a new potential molecule candidate for diagnosis and treatment for renal cancer. Amélia is currently working with Ralf Jocker’s team (Cochin Institute -INSERM Paris) and with CALIXAR team in Lyon on GPR50 and others GPCR targets. CALIXAR as expert in the field of native and functional GPCRs expression and isolation supports and encourages research on GPCR targets. The most talented poster of this session will receive the poster prize 2022 awarded by CALIXAR. About i-GPCRnet: The i-GPCRnet International Research Network (IRN) was founded in 2021 for five years by the CNRS (www.cnrs.fr), the National Centre for Scientific Research of France, an interdisciplinary public research organization that is among the world’s leading research institutions. The mission of the i-GPCRnet IRN is to promote science in the field of G protein-coupled receptors (GPCRs). For more information and meet us: i-GPCRnet  

CALIXAR team will attend the BioPharm America virtual event from October 4 -5, 2022 to have exchanges on commercial and scientific opportunities related to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently expanding its pipeline of highly druggable membrane protein targets and native antigens. In the coming years, CALIXAR will be able to offer pharmaceutical companies validated and discovery-ready native and functional therapeutic targets. CALIXAR aims at becoming a leader in the complex therapeutic targets-based (membrane proteins) drug development at the early discovery stage. Indeed, it is a thriving market expected to be worth 70 billion euros by 2025. About BioPharm America: BioPharm America™ Digital promotes an international audience of investors and industry leaders from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions which creates a robust exchange. It brings dealmakers from the life science ecosystem together to engage and reduce the enormous task of drug development. For more information and meet us: BioPharm America  

CALIXAR team will attend at the EU-Japan Biotech and Pharma virtual partnering conference, from September 26 to 30, 2022 in order to discuss about the commercial and scientific opportunities related to our activities. CALIXAR is a biotech company focused on the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …). The company is currently working on the pipeline extension of highly druggable membrane protein targets and native antigens. In the next few years, CALIXAR will therefore be able to provide to Pharma / Biotech companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR aims at becoming a leader in the complex therapeutic targets-based (membrane proteins) drug development at the early discovery stage. Indeed, it is a thriving market expected to be worth 70 billion euros by 2025. About Bio Japan: The EU-Japan Biotech & Pharma Partnering Conference 2022 offers business contacts to industry professionals who are looking for potential partners in the Biotech and Pharma sector. The event is co-organized by the Osaka Prefectural Government, the EU-Japan Centre for Industrial Cooperation and the Enterprise Europe Network. It will be supported by various Bioclusters from Japan and Europe. For more information and meet us: Bio Japan

CALIXAR team will be present at the online European Antibody Engineering & Therapeutics from June 07 to 09, 2022 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. About Antibody Engineering & Therapeutics Europe Organized by the Antibody Society, the Antibody Engineering & Therapeutics conference is dedicated to scientists to exchange and network in the fields of antibody engineering and therapeutics, immune-biology, and next-generation binders. This is the Europe’s leading antibody conference for accelerating next-generation antibodies to commercial success. The conference includes 8 new hot topic streams. To meet us and discover the agenda: Antibody Engineering & Therapeutics Europe  

CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. Vincent CORVEST, Senior Scientist & Business Manager is glad to be part of the 2022 AMR Conference to exchange on CALIXAR’s capabilities that will be a key point in the development of small molecules, antimicrobial treatments and so on. Meet Vincent during the 2-day event and give yourself the chance to achieve your discovery projects. About the AMR Conference: The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors, and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market. The “AMR Conference” was started in 2017 to offer a platform for meeting experts from business, science, clinics, finance, regulatory affairs, and intellectual property. For more information and meet us: AMR Conference

As part of its collaboration with ASTON University, CALIXAR, a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …) will attend the Birmingham European SMALP on April 06-08, 2022. Afroditi VAITSOPOULOU, PhD student at Aston University (Birmingham, UK), under the supervision of Alice Rothnie and Roslyn Bill joined the CALIXAR team, in Lyon for a few months, to work on the expression and purification of the MRP4 transporter in the framework of the MemTrain collaborative project. Afroditi will present her poster titled “MRP4 expression, extraction and purification using SMA2000, calixarene-based detergents and common detergents” in which she demonstrates the successful use of SMA molecules and calixarene-based detergents (proprietary and unique reagents commercialized by CALIXAR) to extract the MRP4 protein from the membrane by preserving its integrity. With over 10 years of experience in the field of protein extraction and stabilization, CALIXAR uses proprietary and unique reagents to preserve the integrity of native membrane proteins. Alexis Moreno, Project Manager at CALIXAR will also be at Birmingham to discuss this project and to present the solutions proposed by CALIXAR for the extraction and stabilization of membrane proteins. To learn more about CALIXAR’s capabilities and meet us: European SMALP  

Vincent CORVEST, Senior Scientist & Business Manager at CALIXAR will give a talk during the World Vaccine Congress at Washington on 21st April. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). Through its experience in the production and expression of native membrane proteins CALIXAR has developed an innovative proprietary detergent-based approach consisting either in inactivating native viruses while keeping the viral envelope intact, or in improving the solubilization and the stabilization of viral antigens without any mutation, truncation and fusion. Vincent will be pleased to present you our approach to solubilize and stabilize the structural E3-E2-6K-E1 protein complex of the Chikungunya virus (CHIKV) during the conference related to “Emerging and Infectious Diseases”. Meet Vincent during these 4 days of event to learn more on CALIXAR’s proprietary technology and exchange with him on the generation of new drugs, antibodies, or vaccines of challenging virus and bacteria. To join us at this event, we are glad to offer you a 25% discount on your conference ticket by following this link: World Vaccine Congress – 25% About World Vaccine Congress For the past 21 years, the World Vaccine Congress of Washington has evolved and grown into the leading vaccines congress globally, with hundreds of speakers, thousands of attendees, and hundreds of networking opportunities.

CALIXAR team will be present at the online Bio Europe Spring event, from March 28 to 31, 2022 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About Bio Europe Spring BIO-Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. For more information and meet us: Bio Europe Spring

CALIXAR team will attend the online Redefining Early-Stage Investments (RESI) event, from March 22 to 24, 2022 to present its licensing business model and to develop a pipeline of native targets of pharmaceutical interest. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About the Redefining Early-Stage Investments (RESI) The Redefining Early-Stage Investments (RESI) conference series connect start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics, and digital health (4 Ds). RESI caters for both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms seeking for series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare. For more information and meet us: Redefining Early Stage Investments (RESI)

CALIXAR team will be present at the virtual Biotech showcase, January 10–12, 2022 and January 17–19, 2022 to discuss partnering with other biopharmaceutical and life science actors and investors. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About the BIOTECH SHOWCASE: The BIOTECH SHOWCASE is produced each year by Demy-Colton and EBD Group. This event allows companies to connect to thousands of peers from Startup, over Biotech and large Pharma. From early, mid to later stage. This 14th edition will be held online and will feature multiple tracks of curated presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. For more information: BIOTECH SHOWCASE  

CALIXAR team will be present at the online BioFIT event, from December 07 to 09, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to pharmaceutical companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BioFIT: With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs, and emerging biotech companies. Together with big pharma, biotech, and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed, and Series A investment in Life Sciences. For more information and meet us: BioFIT

CALIXAR team will be present at the online i-GPCRnet from November 30th to December 03rd, 2021 to discuss different topics relating to Membrane Proteins and more specifically on GPCRs. G protein-coupled receptors (GPCRs) are among the most important protein families in sensing environmental changes at the cellular level providing them adequate response and adaptation. Their potential as drug targets has been recognized with 30-40% of currently marketed drugs targeting GPCRs. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …) and is constantly improving to deliver the most pure and stable targets to biotechnology and pharmaceutical companies. During the session “Up and coming technologies to targets GPCRs”, Dr. Vincent CORVEST, Senior Scientist and Business Manager at CALIXAR will give a flash presentation on the know-how of CALIXAR on Membrane Proteins and works conducted on GPCRs. About i-GPCRnet: The ambition of the i-GPCRnet is to tackle the largely unexplored question of the impact of the microenvironments on GPCR function and how perturbation of this microenvironment impacts on common diseases such as cancer, metabolic and neurodegenerative diseases as well as their therapies. A better understanding of the GPCR microenvironment holds the promise of unprecedented therapeutic opportunities in terms of tissue specificity and specific pharmacological targeting that will eventually lead to the design of innovative and tailored drugs for precision medicine. To reach this goal the i-GPCRnet consortium will bring together chemists, biophysicists, bioinformaticians, mathematicians, systems and cellular biologists and pharmacologists. For more information and meet us: i-GPCRnet  

CALIXAR team will be on-site workshop at the second APPICOM plenary, from November 15 to 18, 2021 to discuss different topics relating to Membrane Proteins. Membrane therapeutic targets (GPCRs, ion channels, transporters, …) are essential as templates in the development of drug candidates, both in small molecule screening and in the manufacture of therapeutic antibodies, or as antigens in the development of new vaccines. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …) and is constantly improving to deliver the most pure and stable targets to biotechnology and pharmaceutical companies. Chem2stab, the joint laboratory of CALIXAR and the university of Avignon (France) since 2015 will also participate in this event. Grégory Durand and Valentin Monjal, chemists from Chem2Stab will talk about new chemical tools (polymers and sugar-based amphiphilic molecules) for the extraction and stabilization of therapeutic targets without denaturing them. About Appicom: The Group APPICOM gathers 91 research teams coming from 49 research institutes, in France and abroad. APPICOM regroups teams interested in membrane proteins, from biochemical and structural studies to pharmacology and dynamic simulations, and cellular and physiological investigations. APPICOM was created on January 1st, 2020 by the CNRS (French National Research Center), with support from all associated labs Institutional bodies: Universities, INSERM, INRA and CEA. For more information and meet us: APPICOM

CALIXAR team will be present at the online Bio Europe event, from October 25 to 28, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About Bio Europe: The international BIO-Europe® 2021 gathering will be held digitally, standing tall in this time of insecurity, to execute on its pivotal role in bringing the global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs. BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. For more information and meet us: Bio Europe

CALIXAR team will be present at the online Bio Japan event, from October 13 to 15, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About Bio Japan: This event is constituted by three exhibitions – The world’s oldest biotechnology exhibition “BioJapan” (1986), “Regenerative Medicine JAPAN” (2016), aiming at accelerating and industrializing R&D in the field of regenerative medicine including iPS cells, and “health TECH JAPAN”(2020), provides fusion of digital technology and life science. The goal is to provide new value through business partnering of industry, academia, and government which is not limited to Japan, but also from overseas. With the addition of Digital & In-Person partnering program started from 2020, global innovation through this partnering event never stops at all. For more information and meet us: Bio Japan / CALIXAR

CALIXAR team will be present at the online BioPharm America event, from September 20 to 23, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BioPharm America: BioPharm America™ Digital creates a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions. It brings dealmakers from the life science ecosystem together to engage and reduce the enormous task of drug development. For more information and meet us: BioPharm America  

CALIXAR team will be present at the online European Biotech ＆ Pharma Partnering Conference, from September 27 to 30, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About European Biotech ＆ Pharma Virtual Partnering Conference: The European Biotech ＆ Pharma Virtual Partnering Conference 2021 offers business contacts to industry professionals who are looking for potential partners to ensure sustainable business development and growth. The event is co-organized by the Osaka Prefectural Government, the EU-Japan Centre for Industrial Cooperation and it will be supported by the Enterprise Europe Network and various Bioclusters from Japan and Europe.  

CALIXAR team will be present at the online BIO Asia – Taiwan event, from July 21 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BIO Asia – Taiwan event Jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO) the BIO Asia – Taiwan International Conference and Exhibition was held for the first time in 2019.  This year BIO Asia – Taiwan 2021 (online), brings together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia to explore business opportunities with Taiwan’s emerging biotech sector with a unique format of online and live settings. For more information and meet us: BIO Asia – Taiwan

CALIXAR team will be present at the online 9th Antibody Industrial Symposium 2021, from June 22 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About 9th Antibody Industrial Symposium The 9th Antibody Industrial Symposium is an international congress jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign. It is part of the series of Industrial Symposia organized by MAbImprove since 2013. The AIS2021 is the ideal conference for scientists, industrials, physicians and policymakers to exchange about therapeutic antibodies and more! The Scientific committee has set up an exciting program, with keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies. For more information and meet us: 9th Antibody Industrial Symposium

CALIXAR team will be present at the online BIO KOREA International Convention event, from June 9 to 21, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BIO KOREA International Convention BIO KOREA has been held every year since 2006 and serving as a business platform for international bio companies. This 15th-year event brings together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs, through exhibitions, business forums (partnering), and conferences. BIO KOREA has been providing abundant opportunities to assure competitive edges within the convergence industry centered around biotechnology. For more information and meet us: BIO KOREA International Convention

CALIXAR team will attend at the online Redefining Early Stage Investments (RESI) event, from June 8 to 10, 2021 to present its new licensing business model and to develop its pipeline of native targets of pharmaceutical interest. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About the Redefining Early Stage Investments (RESI) The Redefining Early Stage Investments (RESI) conference series connect start-ups and early-stage investors and strategic channel partners. The RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. The RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). For more information and meet us: Redefining Early Stage Investments (RESI)

CALIXAR team will be present at the online Festival of Biologics USA, from March 29 to April 01, 2021 to meet you and discuss about commercial and scientific issues linked to our activities. CALIXAR is a biotech company specialized in the isolation of native membrane therapeutic targets and antigens. This digital event will be a great opportunity to present CALIXAR’s proprietary technologies and know-how to collaborate with academia and industries in the development of innovative drugs and antibodies. About the Festival of Biologics USA: The Festival of Biologics USA is the meeting place for the life science community to bridge the gap between academia and industry. With three events in one (the Americas Antibody Congress, and the World Immunotherapy Congress), this Festival encourages conversation across the entire industry, to inspire change, champion innovation, and address complex challenges that the biologics industry is facing. For more information and meet us: Festival of Biologics USA

CALIXAR team will participate at the 4th Congress of Immunotherapies & Innovations for Infectious Diseases to meet partners working on this thematic and exchange about strategies and scientific issues tied up on its activities.

CALIXAR team will be present at BIO Europe Digital, the October 26-29, 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR team will be present at BIO JAPAN 2020 event online, (October 14-16th, 2020) to meet you and exchange about commercial and scientific opportunities tied up on our activities.

CALIXAR team will be present at Biotech & Pharma Virtual Partnering Conference, the 28 to 30 September 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR team will be present at BIO Digital, the 8-12 June 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR team will attend at Virtual Partnering Event against Covid-19 on 4 to 6 May 2020.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR team will be present at BIO-EUROPE SPRING event at Paris, the 23-25 March 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR to sponsor the 8th annual meeting of GDR3545-GPCR in Montpellier – France.

CALIXAR selected speaker at the EMBO Workshop: Tools for Structural Biology of Membrane Proteins in Hamburg.

Case study of Potassium chloride co-transporter KCC2;

CALIXAR to attend the 17th Annual Discovery on Target Summit in Boston

CALIXAR as invited speaker at the Immuno-technologies Day in Paris.

CALIXAR to attend the 7th Antibody Industrial Symposium in Tours.

CALIXAR to present at the 14th Annual Drug Discovery Chemistry Conference in San Diego.